| ²é¿´: 328 | »Ø¸´: 1 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖú·Òë
|
|
| A question of high priority is whether the approved antiangiogenic regimes are optimally used in terms of dosing, duration, and combination therapy. The role of VEGF (receptor) inhibitors in micrometast atic disease in adjuvant settings (e.g.,upon resection of the primary tumor) will require further research given the paucity of available preclinical data and suitable animal models. |
» ²ÂÄãϲ»¶
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ5È˻ظ´
081700£¬311£¬Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ18È˻ظ´
²ÄÁÏÓ뻯¹¤371Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
336²ÄÁÏÓ뻯¹¤085600Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²ÄÁÏ334Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
331Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ17È˻ظ´
Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏר˶322
ÒѾÓÐ7È˻ظ´

nwsuafliu
ľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 144
- Ó¦Öú: 42 (СѧÉú)
- ½ð±Ò: 2406.9
- É¢½ð: 1449
- ºì»¨: 18
- Ìû×Ó: 1437
- ÔÚÏß: 315.6Сʱ
- ³æºÅ: 136928
- ×¢²á: 2005-12-17
- רҵ: ×÷Îï·Ö×ÓÓýÖÖ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-02-01 22:47:50
yin198716: ½ð±Ò+5, ·ÒëEPI+1, ¡ïÓаïÖú 2013-02-24 12:27:56
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-02-01 22:47:50
yin198716: ½ð±Ò+5, ·ÒëEPI+1, ¡ïÓаïÖú 2013-02-24 12:27:56
| Ò»¸ö¸ß¶ÈÓÅÏÈÎÊÌâÊÇÒѾÅú×¼µÄ¿¹Ñª¹ÜÉú³ÉÖÎÁÆ·½°¸ÊÇ·ñÔÚ¼ÁÁ¿¡¢ÁÆÆÚ¼°ÁªºÏÖÎÁƵȷ½Ã汻ǡµ±²ÉÓ᣼øÓÚȱ·¦¿ÉÓõÄÁÙ´²Êý¾ÝºÍºÏÊʵ͝ÎïÄ£ÐÍ£¬VEGF£¨ÊÜÌ壩ÒÖÖÆ¼ÁÔÚÎ¢×ªÒÆ¼²²¡ÖÐÓÃ×÷¸¨ÖúÒ©£¨ÀýÈ磬Է¢Ö×ÁöÇгý£©Ê±£¬Æä×÷ÓÃÐèÒª½øÒ»²½Ñо¿£¬ |

2Â¥2013-01-31 15:37:08














»Ø¸´´ËÂ¥